Anti-NCR3LG1 / B7-H6 / Natural cytotoxicity triggering receptor 3 ligand 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. The NCR3LG1 antibody targets Natural cytotoxicity triggering receptor 3 ligand 1, a cell surface glycoprotein encoded by the NCR3LG1 gene. Also known as B7H6, this protein serves as a ligand for the activating receptor NKp30 (NCR3) expressed on natural killer (NK) cells. The interaction between B7H6 and NKp30 initiates NK cell activation, cytokine release, and cytotoxic responses against tumor and infected cells. The NCR3LG1 antibody provides a vital tool for studying innate immune surveillance and tumor immunology.Natural cytotoxicity triggering receptor 3 ligand 1 is a type I transmembrane protein belonging to the B7 family of immune regulatory molecules. It is normally absent from healthy tissues but is induced by cellular stress, transformation, or infection. The NCR3LG1 antibody enables researchers to detect B7H6 expression on tumor cells, identifying targets for immune recognition and clearance. Because it acts as a danger signal for NK cell activation, B7H6 is a focus of research in cancer immunotherapy and immune checkpoint modulation.Expression of B7H6 has been reported in various tumors, including leukemia, lymphoma, melanoma, and carcinomas of the lung and ovary. The NCR3LG1 antibody supports studies that examine the relationship between B7H6 expression and tumor immune evasion. Tumor cells may shed soluble B7H6 into the extracellular environment, impairing NK cell function. Detection using the NCR3LG1 antibody allows quantification of both membrane-bound and soluble forms, offering insights into immune escape mechanisms and therapeutic targeting opportunities.In the context of infection, Natural cytotoxicity triggering receptor 3 ligand 1 acts as a stress-induced molecule upregulated by viral or bacterial pathogens, promoting immune activation. The NCR3LG1 antibody supports investigation of these innate immune responses, clarifying how NKp30?B7H6 interactions contribute to early pathogen clearance. Additionally, the ligand's selective expression profile makes it an attractive target for engineered NK cell or bispecific antibody therapies designed to enhance antitumor immunity.The NCR3LG1 antibody is validated for flow cytometry, immunofluorescence, and western blotting, producing distinct membrane staining in positive cell lines. NSJ Bioreagents provides this antibody with strong specificity and consistent performance across immunological assays. By enabling detailed analysis of Natural cytotoxicity triggering receptor 3 ligand 1 expression, the NCR3LG1 antibody supports research into NK cell activation, immune surveillance, and novel cancer immunotherapies.